Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Provance

Gastroenterology Naples, FL Doctor of Osteopathy

NPI 1174517403 CMS profile 144289

681 Goodlette Rd N, Ste 130, Naples, FL 34102

Open in the dashboard

General payments

$74,076

323 records reported · program years 2019–2025

Research payments

$2,408

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$33,187 paid to institutions, not to them · program years 2019–2022

Through program year 2025, William Provance of Naples, FL is reported in the CMS Open Payments database as having received $74,076 across 323 general payments and $2,408 in research payments paid to them. Separately, studies naming them as principal investigator received $33,187 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $317 3
2024 General $220 3
2023 General $14,600 31
2022 General $9,504 56
2021 General $13,368 90
2020 General $10,431 60
2019 General $25,638 80
2019 Research $2,408 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Provance
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to William Provance were reported at $317. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year William Provance Gastroenterology median Middle half National median
2019 $25,638 $417 $126–$1,100 $163
2020 $10,431 $224 $74–$624 $114
2021 $13,368 $352 $106–$1,054 $132
2022 $9,504 $448 $129–$1,270 $149
2023 $14,600 $533 $150–$1,390 $160
2024 $220 $605 $160–$1,606 $164
2025 $317 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gilead Sciences, Inc. $68,740 134 payments
  2. AbbVie, Inc. $1,203 52 payments
  3. Boston Scientific Corporation $1,165 17 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,005 55 payments
  5. Janssen Biotech, Inc. $524 20 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $206 13 payments
  7. Medtronic, Inc. $157 1 payment
  8. Covidien LP $148 1 payment
  9. Janssen Scientific Affairs, LLC $125 1 payment
  10. Regeneron Pharmaceuticals, Inc. $118 1 payment
  11. Other $685 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $58,840 27 payments
  2. Food and Beverage $7,721 266 payments
  3. Travel and Lodging $7,205 26 payments
  4. Education $310 4 payments
Products named General payments · program years 2019–2025
  1. Epclusa $67,957 81 payments
  2. XIFAXAN $981 54 payments
  3. STELARA $649 21 payments
  4. HUMIRA $605 26 payments
  5. EXALT Model D $411 4 payments
  6. MAVYRET $236 11 payments
  7. CREON $178 11 payments
  8. EndoFlip $157 1 payment
  9. Barrx $148 1 payment
  10. SPYGLASS $129 2 payments
  11. Other $1,676 58 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $2,408 2 payments

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$104,903

Medicare's payments for the services billed

Medicare patients

454

Average age 79

Services billed

1,207

228 women, 226 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Ischemic heart disease 61%
Atrial fibrillation 50%
Chronic kidney disease 48%
Heart failure 43%
Depression 37%
Diabetes 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Pharmaceuticals, Inc. $118
$118 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

325 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record